Advantig-105: Phase Ib Dose-Expansion Study Of Ociperlimab (Oci) + Tislelizumab (Tis) With Chemotherapy (Ct) In Patients (Pts) With Metastatic Oesophageal Squamous Cell Carcinoma (Escc) And Oesophageal Adenocarcinoma (Eac)
Ociperlimab;Tislelizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Advantig-105: Phase Ib Dose-Expansion Study Of Ociperlimab (Oci) + Tislelizumab (Tis) With Chemotherapy (Ct) In Patients (Pts) With Metastatic Oesophageal Squamous Cell Carcinoma (Escc) And Oesophageal Adenocarcinoma (Eac) ### Output: Ociperlimab;Tislelizumab